Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial

Archives of General Psychiatry
P J McGrathF M Quitkin

Abstract

Depressive disorders are commonly comorbid with alcoholism, particularly in treatment-seeking samples. If antidepressant treatment were safe and improved the treatment outcome in the subset of actively drinking alcoholics with depression, this would be of clinical importance. We conducted a randomized, 12-week placebo-controlled trial of imipramine hydrochloride combined with weekly relapse prevention psychotherapy. The subjects were 69 actively drinking alcoholic outpatients with current depressive disorders. The first onset of depression was either antecedent to the abuse of alcohol or occurred during prolonged periods of sobriety. Depression and drinking outcomes at 12 weeks, as well as their relationship, were measured. Imipramine treatment was safe and associated with improvement in depression in both adequately treated and intention-to-treat samples. While there was no overall effect on drinking outcome, patients whose mood improved showed decreased alcohol consumption that was more marked in those treated with imipramine. Imipramine treatment is effective for primary depression among actively drinking alcoholic outpatients, and may improve alcoholic outcome for those whose depression responds to treatment.

Citations

Oct 24, 1997·Journal of Consulting and Clinical Psychology·R A BrownT I Mueller
Sep 14, 2006·Current Psychiatry Reports·Edward V Nunes, Frances R Levin
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Michael Soyka, Susanne Roesner
Feb 15, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Jan 27, 2016·Epidemiology and Psychiatric Sciences·R C KesslerA M Zaslavsky
May 1, 2001·Suicide & Life-threatening Behavior·A Roy
Dec 15, 2015·Drug and Alcohol Dependence·Mark StoutenbergJennifer P Read
Dec 19, 2006·American Journal of Preventive Medicine·Uma Rao
Feb 20, 2004·The American Journal on Addictions·Henry R Kranzler, Richard N Rosenthal
May 29, 2004·Alcoholism, Clinical and Experimental Research·Jack R CorneliusThomas M Kelly
Mar 22, 2007·Alcoholism, Clinical and Experimental Research·Quyen Q Tiet, Brent Mausbach
Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·John LiappasAndreas Rabavilas
Nov 24, 2004·Biological Psychiatry·Helen M Pettinati
Apr 21, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Su-Jung YoonChung Tai Lee
Jun 1, 1996·The Psychiatric Clinics of North America·E V NunesP J McGrath
Dec 11, 2003·Obstetrics and Gynecology Clinics of North America·Geetanjali Chander, Mary E McCaul
Nov 20, 2004·The Psychiatric Clinics of North America·Hugh MyrickHamilton Peters
Sep 21, 2011·Pharmacology, Biochemistry, and Behavior·Sheketha R HauserYousef Tizabi
Jul 2, 2005·Journal of Psychiatric Practice·J F Goldberg
Feb 1, 2004·Acta Neuropsychiatrica·M T Abou-Saleh
Sep 1, 2002·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·A Thomas McLellan
Sep 1, 2002·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Kathleen T Brady
Dec 23, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Apr 16, 2004·Alcoholism, Clinical and Experimental Research·Carlos A Hernandez-AvilaHenry R Kranzler
Apr 29, 2004·Alcoholism, Clinical and Experimental Research·Charlene E Le FauveAlan I Green
Nov 12, 2005·Substance Use & Misuse·Kathleen T Brady, Marcia L Verduin
May 26, 2005·Drug and Alcohol Dependence·David McDowellEva Petkova
Apr 27, 2004·Journal of Psychopharmacology·J LiappasG Christodoulou
Sep 23, 2000·Journal of Geriatric Psychiatry and Neurology·D W Oslin
Feb 6, 1998·Psycho-oncology·J C Lundberg, S D Passik
Oct 24, 2003·Alcoholism, Clinical and Experimental Research·Mats BerglundAgneta Ojehagen
Nov 19, 2003·Journal of Clinical Psychopharmacology·Darlene H MoakRamon Durazo-Arvizu
Feb 11, 2004·The Journal of Nervous and Mental Disease·Mark ZimmermanMichael A Posternak
Apr 25, 2018·The Cochrane Database of Systematic Reviews·Roberta AgabioPier Paolo Pani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.